Phase 1: initiation (weeks 1 to 2) Concentration: 1mg/mL suspension
For weight management specifically, NICE TA875 recommends semaglutide (Wegovy) for adults with at least one weight-related comorbidity and a BMI of at least 35 kg/m (or 30 kg/m in exceptional circumstances), delivered through specialist weight management services for up to 2 years
Many Canadians find that injecting on the same day each week helps establish routine and prevents missed doses
The clinical evidence for tirzepatide is compelling, but the patients who achieve the best outcomes are not simply those who inject once a week and hope for the best
Many patients find this area convenient and comfortable, particularly if they have adequate subcutaneous tissue in this region
This medication, which is used to manage Type 2 diabetes, has been shown to cause eructation, or belching, according to the Food and Drug Administration